NCT02334735 - A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2020

Conditions

Melanoma

Interventions

BIOLOGICAL

DC Vaccine

"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10\^6 cells)"

BIOLOGICAL

Montanide Vaccine

250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG

BIOLOGICAL

Poly-ICLC

1.4 mg

Trial Locations (2)

10016

New York University Langone Medical Center, New York

10029

Icahn School of Medicine at Mount Sinai, New York